

Yuxuan Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3799912/publications.pdf>

Version: 2024-02-01

30
papers

10,168
citations

218592

26
h-index

434063

31
g-index

35
all docs

35
docs citations

35
times ranked

15632
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	5.8	3,665
2	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	6.0	1,872
3	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1835-1848.	13.9	451
4	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207.	3.3	438
5	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. <i>JAMA Oncology</i> , 2019, 5, 1710.	3.4	383
6	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. <i>Gastroenterology</i> , 2015, 149, 1501-1510.	0.6	376
7	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. <i>Science Translational Medicine</i> , 2015, 7, 293ra104.	5.8	372
8	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9704-9709.	3.3	317
9	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. <i>Cancer Discovery</i> , 2016, 6, 166-175.	7.7	282
10	Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers. <i>Science Translational Medicine</i> , 2013, 5, 167ra4.	5.8	264
11	Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. <i>Nature Genetics</i> , 2014, 46, 1170-1172.	9.4	247
12	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	6.1	234
13	<i>TERT</i> Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine. <i>Cancer Research</i> , 2013, 73, 7162-7167.	0.4	214
14	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	178
15	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1118.	3.4	152
16	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. <i>ELife</i> , 2018, 7, .	2.8	118
17	Versatile genetic assembly system (VEGAS) to assemble pathways for expression in <i>S. cerevisiae</i> . <i>Nucleic Acids Research</i> , 2015, 43, 6620-6630.	6.5	96
18	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	3.9	88

#	ARTICLE	IF	CITATIONS
19	Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4293-4300.	0.8	87
20	Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	2.3	77
21	Detection of Somatic TP53 Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2014, 124, 881-885.	1.2	44
22	High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 427-434.	1.4	38
23	Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. <i>Human Pathology</i> , 2016, 53, 8-13.	1.1	31
24	Diagnostic potential of tumor DNA from ovarian cyst fluid. <i>ELife</i> , 2016, 5, .	2.8	30
25	Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 761-767.	1.4	29
26	Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. <i>Human Pathology</i> , 2019, 85, 1-9.	1.1	28
27	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3516-3516.	0.8	19
28	Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4733-4738.	3.3	12
29	Circulating tumor DNA (ctDNA) in nonmetastatic colorectal cancer (CRC): Potential role as a screening tool.. <i>Journal of Clinical Oncology</i> , 2015, 33, 518-518.	0.8	6
30	Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA100-LBA100.	0.8	5